Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
- Citation:
- Lung Cancer vol 76 (3) 393-6
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 1
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA031946, U10 CA033601
- Corr. Author:
- Authors:
- Thierry Jahan Lin Gu Robert Kratzke Arkadiusz Dudek Gregory A Otterson Xiaofei Wang Mark Green Everett E Vokes Hedy Lee Kindler
- Networks:
- Study
- CALGB-30107
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Aged, Aged, 80 and over, Antineoplastic Agents, Female, GPI-Linked Proteins, Humans, Male, Mesothelioma, Middle Aged, Phthalazines, Platelet-Derived Growth Factor, Protein Kinase Inhibitors, Pyridines, Survival Analysis, Thrombospondin 1, Treatment Outcome, Tumor Markers, Biological, Vascular Endothelial Growth Factor A